Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 10:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 426 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: VEGF Clear all
Terminated No phase listed Observational

Anti-VEGF Therapy for Subfoveal Hemorrhage in Patients With Neovascular Age-Related Macular Degeneration

NCT03699618
View directory record Official record
Conditions
Submacular Hemorrhage, Wet Macular Degeneration, Neovascular Age-related Macular Degeneration
Interventions
Anti-VEGF, Hemorrhage displacement + Anti-VEGF
Drug · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
50 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 19, 2020 · Synced Oct 31, 2026, 10:53 AM EDT
Completed Phase 2 Interventional

Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Malignant Mesothelioma

NCT00027703
View directory record Official record
Conditions
Advanced Malignant Mesothelioma, Epithelial Mesothelioma, Localized Malignant Mesothelioma, Recurrent Malignant Mesothelioma, Sarcomatous Mesothelioma
Interventions
gemcitabine hydrochloride, cisplatin, bevacizumab, placebo, laboratory biomarker analysis
Drug · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 11, 2014 · Synced Oct 31, 2026, 10:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

NVAMD Satellite Study

NCT02251366
View directory record Official record
Conditions
Neovascular Age Related Macular Degeneration
Interventions
Physician-guided diagnostic
Procedure
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
5
States / cities
Bel Air, Maryland • Bethesda, Maryland • Columbia, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2018 · Synced Oct 31, 2026, 10:53 AM EDT
Completed Phase 1 Interventional

Dasatinib in Combination With Bevacizumab to Treat Advanced Solid Tumors

NCT01445509
View directory record Official record
Conditions
Solid Tumors
Interventions
Bevacizumab, Dasatinib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Oct 31, 2026, 10:53 AM EDT
Completed No phase listed Observational

Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Agerelated Macular Degeneration (AMD) Who Received Anti-VEGF Agents (IRIS Registry)

NCT05110209
View directory record Official record
Conditions
Age-related Macular Degeneration (AMD)
Interventions
Aflibercept, Ranibizumab, Bevacizumab
Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
331,541 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 21, 2021 · Synced Oct 31, 2026, 10:53 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma

NCT02974621
View directory record Official record
Conditions
Recurrent Glioblastoma
Interventions
Bevacizumab, Cediranib, Cediranib Maleate, Olaparib
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
27
States / cities
La Jolla, California • Aurora, Colorado • Derby, Connecticut + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 31, 2026, 10:53 AM EDT
Completed Phase 2 Interventional Results available

Bevacizumab in Treating Patients With Unresectable Nonmetastatic Liver Cancer

NCT00055692
View directory record Official record
Conditions
Adult Primary Hepatocellular Carcinoma, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
Interventions
bevacizumab
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Feb 29, 2016 · Synced Oct 31, 2026, 10:53 AM EDT
Completed Phase 2 Interventional Results available

Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell Carcinoma

NCT03173560
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
lenvatinib, everolimus
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
343 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
8
States / cities
Duarte, California • Whittier, California • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Oct 31, 2026, 10:53 AM EDT
Completed Phase 1 Interventional

A Pilot Trial of Oral Topotecan for the Treatment of Refractory Advanced Solid Neoplasms Expressing HIF-1a

NCT00117013
View directory record Official record
Conditions
Neoplasms
Interventions
Fluorine-19-Fluoroded Xyglucose, Topotecan
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 31, 2026, 10:53 AM EDT
Completed Phase 4 Interventional Results available

Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Alone Versus Ozurdex Given Every 3 Months for Treatment of Persistent Diabetic Macular Edema

NCT02036424
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Ozurdex, Bevacizumab
Drug
Lead sponsor
Raj K. Maturi, MD
Individual
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 1, 2015 · Synced Oct 31, 2026, 10:53 AM EDT
Completed Phase 3 Interventional

Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Previously Treated Metastatic Colorectal Cancer

NCT00056446
View directory record Official record
Conditions
Colorectal Neoplasms, Colonic Neoplasms, Rectal Neoplasms
Interventions
Vatalanib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
855 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
143
States / cities
Huntsville, Alabama • Anchorage, Alaska • Tucson, Arizona + 113 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2017 · Synced Oct 31, 2026, 10:53 AM EDT
Withdrawn Phase 2 Interventional

A Safety and Efficacy Study of Carbidopa-levodopa in Patients With Macular Degeneration

NCT02873351
View directory record Official record
Conditions
Age-related Macular Degeneration
Interventions
carbidopa-levodopa 25-100 mg, placebo for carbidopa-levodopa 25-100 mg
Drug
Lead sponsor
Snyder, Robert W., M.D., Ph.D., P.C.
Individual
Eligibility
50 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 5, 2019 · Synced Oct 31, 2026, 10:53 AM EDT
Active, not recruiting Phase 2 Interventional

CLOVER - CCR5-targeting Leronlimab With Oral Chemotherapy and VEGF-inhibitor Enriched Regimen

NCT06699836
View directory record Official record
Conditions
Metastatic Colorectal Cancer (mCRC)
Interventions
350 mg leronlimab, 700 mg leronlimab, 200 mg pembrolizumab
Drug
Lead sponsor
CytoDyn, Inc.
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
7
States / cities
Irvine, California • San Francisco, California • Washington D.C., District of Columbia + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 31, 2026, 10:53 AM EDT
Completed Phase 2 Interventional Results available

A Study of Niraparib Combined With Bevacizumab Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

NCT03326193
View directory record Official record
Conditions
Ovarian Neoplasms
Interventions
Niraparib, Bevacizumab
Drug · Biological
Lead sponsor
Tesaro, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
29
States / cities
Mobile, Alabama • Anchorage, Alaska • Mesa, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2025 · Synced Oct 31, 2026, 10:53 AM EDT
Completed Phase 1 Interventional

Aflibercept in Treating Young Patients With Relapsed or Refractory Solid Tumors

NCT00622414
View directory record Official record
Conditions
Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
ziv-aflibercept
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 21 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
6
States / cities
Chicago, Illinois • Boston, Massachusetts • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2014 · Synced Oct 31, 2026, 10:53 AM EDT
Completed No phase listed Observational

Evaluation of the Association Between Genetic Load and Response to Anti-VEGF Therapy in AMD Patients

NCT01644513
View directory record Official record
Conditions
Age Related Macular Degeneration
Interventions
Not listed
Lead sponsor
Sequenom, Inc.
Industry
Eligibility
55 Years and older
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 12, 2013 · Synced Oct 31, 2026, 10:53 AM EDT
Completed Phase 2 Interventional

Bevacizumab, Cytarabine, and Mitoxantrone on Treating Patients With Hematologic Cancers

NCT00015951
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes
Interventions
bevacizumab, cytarabine, mitoxantrone hydrochloride
Biological · Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
3
States / cities
Atlanta, Georgia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 17, 2019 · Synced Oct 31, 2026, 10:53 AM EDT
Completed Phase 2 Interventional Results available

Dorzolamide-timolol Drops With Injections to Treat AMD, RVO or DME.

NCT02571972
View directory record Official record
Conditions
Wet Macular Degeneration, Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion
Interventions
Dorzolamide-timolol
Drug
Lead sponsor
Wills Eye
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 3, 2019 · Synced Oct 31, 2026, 10:53 AM EDT
Completed Phase 4 Interventional Results available

Study EvAluating Genotypes While Using Lucentis 2

NCT01464723
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
Ranibizumab
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
50 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 14, 2019 · Synced Oct 31, 2026, 10:53 AM EDT
Completed Phase 2 Interventional Results available

Study of the Intravitreal Plasma Kallikrein Inhibitor, KVD001, in Subjects With Center-involving Diabetic Macular Edema (ciDME)

NCT03466099
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
KVD001 Injection, Sham Procedure
Drug · Other
Lead sponsor
KalVista Pharmaceuticals, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
35
States / cities
Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2021 · Synced Oct 31, 2026, 10:53 AM EDT
Completed Phase 1 Interventional

A Pilot Study of EZN-2968, an Antisense Oligonucleotide Inhibitor of HIF-1alpha, in Adults With Advanced Solid Tumors With Liver Metastases

NCT01120288
View directory record Official record
Conditions
Neoplasms, Liver Metastases
Interventions
EZN-2968
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Oct 31, 2026, 10:53 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Measuring Corneal Cells With Specular Microscopy

NCT01792154
View directory record Official record
Conditions
Retinal Diseases
Interventions
Not listed
Lead sponsor
Retina Institute of Hawaii
Other
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Feb 15, 2013 · Synced Oct 31, 2026, 10:53 AM EDT
Recruiting Phase 2Phase 3 Interventional

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)

NCT06712316
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Pumitamig, Pembrolizumab, Carboplatin, Pemetrexed, Paclitaxel
Drug
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
1,580 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
53
States / cities
Birmingham, Alabama • Anchorage, Alaska • Concord, California + 46 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 31, 2026, 10:53 AM EDT
Completed Phase 2 Interventional Results available

Chemoembolization and Bevacizumab in Treating Patients With Liver Cancer That Cannot Be Removed With Surgery

NCT00049322
View directory record Official record
Conditions
Liver Cancer
Interventions
bevacizumab
Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 1, 2020 · Synced Oct 31, 2026, 10:53 AM EDT